GenSight Biologics announces the availability of a prospectus in connection with the listing of new shares on Euronext Paris

GenSight Biologics announces a successful offering for an amount of approximately €4.7 million

GenSight Biologics announces launch of an offering for an indicative amount of €5 million that has received subscription commitments from new and existing shareholders totaling €4 million

GenSight Biologics Confirms 2nd Successful GMP Batch of LUMEVOQ® and Eligibility to Draw Down Bridge Financing 2nd Tranche of €4 million

GenSight Biologics Announces Preliminary Assay Indicating Successful Manufacture of Second LUMEVOQ® GMP Batch

GenSight Biologics Reports Cash Position as of September 30, 2023, and Provides Business Update

GenSight Biologics Provides Update on European Medicines Agency Scientific Advice for LUMEVOQ®

GenSight Biologics Announces Successful Manufacture of LUMEVOQ® GMP Batch

GenSight Biologics Reports Interim Financial Results for the First Half of 2023

GenSight Biologics obtains funding of €10 million from Sofinnova Partners, Invus and UPMC Enterprises